Sept 11 (Reuters) – AstraZeneca said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)
Comments